Thomas Helland

Guest Researcher

Show author(s) (2022). Liquid biopsies and patient-reported outcome measures for integrative monitoring of patients with early-stage breast cancer: a study protocol for the longitudinal observational Prospective Breast Cancer Biobanking (PBCB) study. BMJ Open.

Show author(s) (2021). Generating a precision endoxifen prediction algorithm to advance personalized tamoxifen treatment in patients with breast cancer. Journal of Personalized Medicine. 1-23.
Show author(s) (2021). Effect of genetic variability in 20 pharmacogenes on concentrations of tamoxifen and its metabolites. Journal of Personalized Medicine. 11 pages.
Show author(s) (2021). Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial. NPJ breast cancer. 1-34.

Show author(s) (2020). Relationship between CYP2D6 genotype, tamoxifen metabolites, and adverse events, tumor biomarkers and breast cancer recurrence in a low-dose phase III trial in noninvasive disease. Journal of Clinical Oncology.
Show author(s) (2020). Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen. Molecular Oncology. 11 pages.
Show author(s) (2020). First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: A case study. ESMO Open. 1-5.

Show author(s) (2019). Tamoxifen in the treatment of luminal breast cancer. Implications of active metabolites on gene expression, side effects and clinical outcome.
Show author(s) (2019). Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database. Breast Cancer Research and Treatment. 185-195.

Show author(s) (2018). A prospective, longitudinal, breast cancer biobank (PBCB) in western Norway.